Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ef20080275_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S.
EX-99.1 2 ef20080275_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, August 14, 2026 – Femasys Inc . (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. Corporate Highlights from 2Q 2026 to date • Completed $30 million private placement with potential proceeds of up to $90 million upon full cash exercise of warrants. • Regain...
Source
Exhibit EX-99.1
0001140361-26-033145
Filed August 14, 2026 at 8:11 PM UTC. The figures above are from the audited statements, not from this release.